RESULTS

N6-methyladenosine methylation-regulated PLK1 cell cycle as a potential target of pancreatic adenocarcinoma (Scientific Reports, 2022)

In the international collaboration with Department of Radiation Oncology, Osaka University Graduate School of Medicine, Japan (Professor Ogawa), Dr. Tatekawa studied the mechanism of RNA modification. Given that methyltransferase-like 3 (METTL3), a N6-methyladenosine (m6A) methyltransferase has a favorable effect on tumors, we report that polo-like kinase 1 (PLK1) is an important hub gene in the RNA methylation, suggesting that PLK1 is essential for cell cycle maintenance and is a new therapeutic target in pancreatic cancer.